Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Chemotherapy When Renal Function is Impaired: For All Patients or For Some Patients? Although almost half of patients diagnosed with advanced bladder cancer cannot receive cisplatin, optimal ...

Management: Transurethral resection of the bladder tumor, clinical trialbased neoadjuvant treatment with paclitaxel, carboplatin and gemcitabine ... of theBladder Cancer Research Program.

If you or a loved one has gallbladder or bile duct cancer, you may be interested in learning more about treatments for it. For a long time, the standard treatment options for this cancer type ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by ... durvalumab combined with neoadjuvant gemcitabine–cisplatin (followed by radical surgery ...

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed ... it it is being used to deliver the chemotherapy agent gemcitabine. In a statement, J&J said that the trial ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Immunotherapy improved overall survival when added to cisplatin-gemcitabine ... selection of chemotherapy backbones in immunotherapy regimens for mUC [metastatic urothelial cancer], promoting ...

The TROP2-directed antibody-drug conjugate failed to top chemotherapy at extending the lives of bladder cancer patients who had tried a PD-1/L1 therapy and chemo. Detailed data of that flop have ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...